Alloy Review
Best for: women in menopause with comprehensive GLP-1 formulary needs (pending verification)
Alloy is a menopause-focused telehealth brand offering a weight care program that includes brand-name Zepbound and Wegovy plus compounded semaglutide, tirzepatide, and liraglutide. 48 states (not available in Louisiana or Mississippi).
Low confidence · Last verified 2026-04-09 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Alloy is a solid telehealth option with balanced features and pricing.
Score Breakdown
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Preliminary | compounded | $199 |
| Preliminary | brand | $650 |
✓ Pros
- •Broad GLP-1 formulary including Zepbound, Wegovy, compounded sema, tirz, and liraglutide
- •48-state coverage
- •Menopause specialty framing — addresses a demographic where GLP-1 care intersects with hormone therapy
✗ Cons
- •Not available in Louisiana or Mississippi
- •Menopause-focused — targets women in a specific life stage, not a general GLP-1 telehealth
- •Stub entry — exact pricing and insurance coordination need YMYL verification
Ready to start with Alloy?
Starting at $199/month. See current pricing and start your free consultation.
Sources & methodology
Our Alloy review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
Alternatives to Alloy
Editorial score · methodology
Editorial score · methodology
Amazon Pharmacy
Best for: fastest brand-name Foundayo delivery with the cheapest insured price
Editorial score · methodology
Frequently Asked Questions
Ready to start with Alloy?
Starting at $199/month. See current pricing and start your free consultation.